ArticleFrontiers in microbiology2025
Tibetan herbal medicine
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Effects of High-Altitude Environments on Gut Microbiota and Their Mechanisms in Immune Regulation and High-Altitude Adaptation.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hypoxic pulmonary hypertension (HPH) is a severe high-altitude disorder with limited therapeutic options. This study investigated the therapeutic mechanisms of Methods: HPH was induced in male Sprague-Dawley rats exposed to chronic hypoxia. Animals were randomly assigned to normoxic control, hypoxic model, OFB-treated, or Rhodiola-treated groups. Serum metabolomics (LC-MS) and 16S rRNA sequencing of fecal microbiota were performed. Cardiopulmonary parameters including RVSP and RVHI were assessed, and pulmonary arterial ultrastructure was examined. Results: OFB significantly attenuated HPH-induced elevations in RVSP and RVHI and mitigated pulmonary arterial remodeling. Metabolomic analysis identified 25 differentially regulated metabolites in HPH, primarily involved in pyrimidine metabolism, which were largely restored by OFB. OFB also reversed HPH-induced gut microbiota dysbiosis, restoring microbial diversity and composition toward normoxic levels. Correlation analysis revealed significant associations between specific bacterial taxa and altered metabolites. Conclusions: These findings suggest that OFB exerts therapeutic effects against HPH by modulating gut microbiota dysbiosis and restoring metabolic homeostasis, particularly within pyrimidine metabolism. The observed gut-lung axis interactions may underlie these effects, offering novel mechanistic insights and supporting the potential clinical development of OFB as a microbiota-targeted therapy for HPH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.